C9146 — Injection, mirvetuximab soravtansine-gynx, 1 mg
C9146 is a HCPCS Level II code for injection, mirvetuximab soravtansine-gynx, 1 mg. It belongs to the Outpatient Prospective Payment System section. It was terminated on June 30, 2023 and is not valid on new claims.
This code has been terminated
CMS terminated C9146 on June 30, 2023. It stays in the file as history — a claim you are auditing from before that date may legitimately carry it — but it must not appear on a new claim. The adjacent codes below are the usual place to look for its replacement.
Medicare coverage: Special coverage instructions apply
There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.
The CMS record for C9146
- Long descriptor
- Injection, mirvetuximab soravtansine-gynx, 1 mg
- Short descriptor
- Inj, elahere, 1 mg
- Added
- April 1, 2023
- Terminated
- June 30, 2023
- BETOS
- O1E
- Pricing indicator
- 53 — Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
When CMS retired it.
Berenson-Eggers Type of Service — CMS's own analytic grouping.
Statute.
Codes adjacent to C9146
HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If C9146 is not quite right, the correct code is very often within a few positions of it.
- C9138Injection, factor viii (antihemophilic factor, recombinant) (nuwiq), 1 i.u.terminated
- C9139Injection, factor ix, albumin fusion protein (recombinant), idelvion, 1 i.u.terminated
- C9140Injection, factor viii (antihemophilic factor, recombinant) (afstyla), 1 i.u.terminated
- C9141Injection, factor viii, (antihemophilic factor, recombinant), pegylated-aucl (jivi), 1 i.u.terminated
- C9142Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mgterminated
- C9143Cocaine hydrochloride nasal solution (numbrino), 1 mg
- C9144Injection, bupivacaine (posimir), 1 mg
- C9145Injection, aprepitant, (aponvie), 1 mgterminated
- C9147Injection, tremelimumab-actl, 1 mgterminated
- C9148Injection, teclistamab-cqyv, 0.5 mgterminated
- C9149Injection, teplizumab-mzwv, 5 mcgterminated
- C9150Xenon xe-129 hyperpolarized gas, diagnostic, per study doseterminated
- C9151Injection, pegcetacoplan, 1 mgterminated
- C9152Injection, aripiprazole, (abilify asimtufii), 1 mgterminated
- C9153Injection, amisulpride, 1 mgterminated
- C9154Injection, buprenorphine extended-release (brixadi), 1 mgterminated
Questions about C9146
What is HCPCS code C9146?
C9146 is a HCPCS Level II code for injection, mirvetuximab soravtansine-gynx, 1 mg. It sits in the Outpatient Prospective Payment System section.
Does Medicare cover C9146?
The CMS HCPCS file marks C9146 as "Special coverage instructions apply". There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
Is C9146 still valid?
No. C9146 was terminated on June 30, 2023 and should not be used on new claims.